Faculty profile

Laurent Azoulay

ResearcherOncologyMcGill University

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a McGill University directory, so their courses may be missing. Find their university profile.

Laurent Azoulay

Researcher

Oncology

Health Sciences

McGill University

Montreal, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
55 publications in the last five years, latest in 2026.
Senior (last) author on 29 recent papers, a sign of leading a research group.
Principal investigator on 13 research grants (13 CIHR), most recently in 2025.
Supervised 3 trainees who won CIHR awards, most recently in 2024.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

212

Publications

474

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Pharmacoepidemiology Population-Based Type 2 Diabetes Drug Safety Drug Effectiveness Glp-1 Receptor Agonists Obesity Epidemiology

Latest papers

Incretin-Based Drugs and the Risk of Dementia Among Patients with Type 2 Diabetes.
Drug safety · 2026
The association between pre-existing type 2 diabetes on cancer-related and all-cause mortality among women with breast cancer.
Breast cancer research and treatment · 2026 · senior author
Glucagon-Like Peptide 1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients With Type 2 Diabetes.
Diabetes care · 2026 · senior author

All 212 publications

Latest funding

Steatotic Liver Disease, Fibrosis and Inflammatory Bowel Disease: Uncovering the Triple Threat
CIHR · 2026 · Co-investigator
$1,005,976
GLP-1 Receptor Agonists in Older Adults: Weighing Cardiovascular Benefits Against Frailty-Related Risks
CIHR · 2025 · Nominated PI
$397,800
Incretin-mimetic drugs for cancer prevention: Mechanisms and clinical potential
CIHR · 2025 · Principal investigator

All 33 grants and awards

From the 150 most recent of 212 publications.

Incretin-Based Drugs and the Risk of Dementia Among Patients with Type 2 Diabetes.

Wang YH, Johnson K, Beradid S, Yin H, Yu OHY, Suissa S, Azoulay L, Renoux C

Drug safety2026

DOI: 10.1007/s40264-025-01623-9 PMID: 41123870

The association between pre-existing type 2 diabetes on cancer-related and all-cause mortality among women with breast cancer.

Parsons K, Yin H, Yu OHY, Khosrow-Khavar F, Azoulay L

Breast cancer research and treatment2026Senior author

DOI: 10.1007/s10549-026-07913-9 PMID: 41661345

Glucagon-Like Peptide 1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients With Type 2 Diabetes.

Noh Y, Yin H, Ben Ghezala I, Yu OHY, Suissa S, Azoulay L

Diabetes care2026Senior author

DOI: 10.2337/dc25-2577 PMID: 41701611

Effectiveness of GLP-1 receptor agonists to prevent obstructive sleep apnea in patients with type 2 diabetes: active comparator, new user cohort study.

Khouri C, Dell'Aniello S, Jambon Barbara C, Azoulay L, Suissa S, Pepin JL

American journal of respiratory and critical care medicine2026

DOI: 10.1093/ajrccm/aamag474 PMID: 42745463

Incretin-Based Drugs and the Incidence of Endometrial Cancer Among People with Type 2 Diabetes: Active Comparator New-User Design.

Rothman SM, Yin H, Yu OHY, Pollak M, Azoulay L

Drug safety2025Senior author

DOI: 10.1007/s40264-025-01551-8 PMID: 40347221

Response to Comment on Pradhan et al. Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and the Prevention of Cirrhosis Among Patients With Type 2 Diabetes. Diabetes Care 2025;48:444-454.

Pradhan R, Azoulay L

Diabetes care2025Senior author

DOI: 10.2337/dci25-0052 PMID: 40690649

Proton pump inhibitors use and risk of inflammatory bowel disease in children.

Noh Y, Choi A, Lee H, Yon DK, Kim HS, Kim S, Shin JY, Azoulay L

Gut2025Senior author

DOI: 10.1136/gutjnl-2025-337345 PMID: 41475980

Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and the Prevention of Cirrhosis Among Patients With Type 2 Diabetes.

Pradhan R, Yin H, Lu S, Sebastiani G, Yu O, Suissa S, Azoulay L

Diabetes care2025Senior author

DOI: 10.2337/dc24-1903 PMID: 39774820

Glucagon-Like Peptide-1 Receptor Agonists and Risk for Gastroesophageal Reflux Disease in Patients With Type 2 Diabetes : A Population-Based Cohort Study.

Noh Y, Yin H, Yu OHY, Bitton A, Azoulay L

Annals of internal medicine2025Senior author

DOI: 10.7326/annals-24-03420 PMID: 40658955

Variants of physiological FDG vascular activity on digital PET.

Yin P, Maliha PG, Ebrahim A, Ben-Ezra N, Azoulay L, Vladovsky M, Probst S, Abikhzer G

Nuclear medicine communications2025

DOI: 10.1097/mnm.0000000000001935 PMID: 39604276

Something wrong or missing on this profile? Suggest a correction

Laurent Azoulay

Research

Latest papers

Latest funding

Incretin-Based Drugs and the Risk of Dementia Among Patients with Type 2 Diabetes.

The association between pre-existing type 2 diabetes on cancer-related and all-cause mortality among women with breast cancer.

Glucagon-Like Peptide 1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients With Type 2 Diabetes.

Effectiveness of GLP-1 receptor agonists to prevent obstructive sleep apnea in patients with type 2 diabetes: active comparator, new user cohort study.

Incretin-Based Drugs and the Incidence of Endometrial Cancer Among People with Type 2 Diabetes: Active Comparator New-User Design.

Response to Comment on Pradhan et al. Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and the Prevention of Cirrhosis Among Patients With Type 2 Diabetes. Diabetes Care 2025;48:444-454.

Proton pump inhibitors use and risk of inflammatory bowel disease in children.

Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and the Prevention of Cirrhosis Among Patients With Type 2 Diabetes.

Glucagon-Like Peptide-1 Receptor Agonists and Risk for Gastroesophageal Reflux Disease in Patients With Type 2 Diabetes : A Population-Based Cohort Study.

Variants of physiological FDG vascular activity on digital PET.

Frequent collaborators

Laurent Azoulay

Samy Suissa

Christel Renoux

Antonios Douros

Richeek Pradhan

Oriana Yu

Michael Pollak

Christina Greenaway

Soham Rej

Paul Brassard

Gerald Batist

Alain Bitton

J Michael Paterson

Lambert Busque

Vicky Tagalakis

Madeleine Durand

Madeleine Durand

Marylise Boutros

Gerald Batist

Andrea Benedetti

Mahyar Etminan

Gordon Guyatt

Phyllis Zelkowitz